SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language
International | eng
Country Language

Omnilink Elite™ Vascular Balloon-Expandable Stent System

Ordering Information
Omnilink Elite

Elite engineering and performance.

Strength and flexibility that provides superb results in the iliacs.

Engineering

  • Cobalt chromium multi-link technology that allows for thin struts without sacrificing strength for flexibility and vessel conformability
  • Superb accuracy with no stent shortening^
  • Thin struts* to minimize vessel wall injury1
  • Dual-layer balloon for a low profile system to treat difficult-to-reach lesions

Clinical Results

  • 97.0% clinically driven freedom from TLR at 9 months
  • 91.9% patency in TASC C lesions at 2 years in iliacs2*
  • 84.8% patency in TASC D lesions at 2 years in iliacs2**

High Freedom from Clinically-Driven TLR through 3 Years

Event-Free Survival through 3 Years

Significant Improvement in Walking Capacity as Measured by WIQ

WIQ Mean Score
Stent Loop

Compliance

Nominal and Rated Burst Pressures

WIQ Mean Score
Stent Close-up

Stent Sizes and Specifications

Stent Sizes and Specifications

Data on file at Abbott unless otherwise noted.

^-1.81% shortening for 8.0 mm x 38 mm size.
*Combined clinical results from BRAVISSIMO study where 66%/34% of TASC C lesions were treated with Absolute Pro™ Vascular Self-Expanding Stent System / Omnilink Elite™ Vascular Balloon-Expandable Stent System respectively.
**Combined clinical results from BRAVISSIMO study where 54%/46% of TASC D lesions were treated with Absolute Pro™ Vascular Self-Expanding Stent System / Omnilink Elite™ Vascular Balloon-Expandable Stent System respectively.
^^Compatible with sheath inner diameters of 2.15 and 2.20 mm for 9 mm x 39 mm, 59 mm and 10 mm x 19 mm, 29 mm, 39 mm stents, respectively.
†Omnilink Elite™ PERIPHERAL Vascular Balloon-Expandable Stent System Instructions For Use (IFU). Refer to IFU for additional information.
 

References

  1. Pache, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. JACC 2003; 41:1283-8.
  2. Donato, G. et al. 24-Month Data from the BRAVISSIMO: A Large-Scale Prospective Registry on Iliac Stenting for TASC A & B and TASC C & D Lesions. Annals of Vascular Surgery. 2015; 29(4): 738-750.

MAT-2116360 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2023 Abbott. All Rights Reserved.

MAT-2001111 v5.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

MAT-2305078 v1.0